CN101869558A - 二乙酰二脱水卫矛醇的抗血管生成及肿瘤转移作用 - Google Patents
二乙酰二脱水卫矛醇的抗血管生成及肿瘤转移作用 Download PDFInfo
- Publication number
- CN101869558A CN101869558A CN200910130999A CN200910130999A CN101869558A CN 101869558 A CN101869558 A CN 101869558A CN 200910130999 A CN200910130999 A CN 200910130999A CN 200910130999 A CN200910130999 A CN 200910130999A CN 101869558 A CN101869558 A CN 101869558A
- Authority
- CN
- China
- Prior art keywords
- diacetyldianhydrogalactitol
- angiogenesis
- diacetyl
- metastasis
- dulcit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明是一种已知化学药物二乙酰二脱水卫矛醇的新用途。通过体外和体内实验证实，二乙酰二脱水卫矛醇能抑制血管的生成和抗肿瘤转移。因此，可用于抗肿瘤血管生成及肿瘤的转移。
Description
技术领域
本发明是一种已知化学药物二乙酰二脱水卫矛醇的新用途。
背景技术
二乙酰二脱水卫矛醇是一种烷化剂类抗肿瘤药物。临床上主要用于肝癌，结肠癌和脑瘤的治疗。
发明内容
二乙酰二脱水卫矛醇具有明显的抗血管生成和肿瘤转移作用。
具体实施方式
一、小鼠肝癌H22脾内移植后转移模型
二乙酰二脱水卫矛醇不同浓度组对小鼠肝癌H22脾内移植后转移有明显抑制作用，抑制率均大于30％。
二、人肝癌Bel-7402-F06脾内移植后转移模型
二乙酰二脱水卫矛醇不同浓度组对人肝癌Bel-7402-F06脾内移植后转移有明显抑制作用，抑制率均大于60％。
三、小鼠黑色素瘤B16-F10-luc尾静脉注射后肺转移模型
二乙酰二脱水卫矛醇不同浓度组对小鼠黑色素瘤B16-F10-luc尾静脉注射后肺转移有明显抑制作用，抑制率均大于80％。
四、大鼠主动脉片血管生成模型
二乙酰二脱水卫矛醇不同浓度组对大鼠主动脉片血管发生率具有明显抑制作用，血管发生抑制率均大于50％。
五、体内和血管内皮细胞实验证实，二乙酰二脱水卫矛醇可抑制血管的生成，抑制率达50％以上；同时也可抑制血管内皮细胞的增殖和细胞的运动抑制率达40％-70％，该作用与二乙酰二脱水卫矛醇抑制细胞内VEGF有关。
Claims (1)
1.一种治疗或预防肿瘤转移的方法，包括给药于患有各种肿瘤的哺乳动物有疗效用量的二乙酰二脱水卫矛醇及其药学可接受的盐。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910130999A CN101869558A (zh) | 2009-04-22 | 2009-04-22 | 二乙酰二脱水卫矛醇的抗血管生成及肿瘤转移作用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910130999A CN101869558A (zh) | 2009-04-22 | 2009-04-22 | 二乙酰二脱水卫矛醇的抗血管生成及肿瘤转移作用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101869558A true CN101869558A (zh) | 2010-10-27 |
Family
ID=42994766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910130999A Pending CN101869558A (zh) | 2009-04-22 | 2009-04-22 | 二乙酰二脱水卫矛醇的抗血管生成及肿瘤转移作用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101869558A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106659765A (zh) * | 2014-04-04 | 2017-05-10 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
-
2009
- 2009-04-22 CN CN200910130999A patent/CN101869558A/zh active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106659765A (zh) * | 2014-04-04 | 2017-05-10 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
| CN106659765B (zh) * | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
| US11541027B2 (en) | 2014-04-04 | 2023-01-03 | Del Mar Pharmaceuticals (Bc) Ltd. | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011012513A (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| JP2012136540A5 (zh) | ||
| WO2011112953A3 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| WO2017177149A3 (en) | Methods and compositions for car t cell therapy | |
| UA104600C2 (ru) | Комбинированная терапия с применением пептида эпоксикетона | |
| WO2001074376A3 (en) | Cathepsin inhibitors in cancer treatment | |
| WO2010059253A3 (en) | Methods and compositions for localized agent delivery | |
| WO2011119857A3 (en) | Intravascular tissue disruption | |
| WO2009114826A3 (en) | Treatment systems and methods for renal-related diseases | |
| WO2012107908A3 (en) | Nts-polyplex nanoparticles system for gene therapy of cancer | |
| WO2012038504A3 (en) | Breast cancer therapeutics | |
| MX336013B (es) | Dispositivos, sistemas y metodos de administracion terapeuticos. | |
| WO2008056368A3 (en) | Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases | |
| WO2017091885A8 (en) | Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer | |
| ECSP11011314A (es) | Combinaciones farmacéuticas que comprenden rdea119/bay 869766 para el tratamiento de cánceres específicos | |
| WO2013090523A3 (en) | Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery | |
| WO2012135656A3 (en) | Intra-luminal access apparatus and methods of using the same | |
| MX2013006319A (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. | |
| MX2015003343A (es) | Tratamiento combinado con el farmaco de interferencia de netrina-1 y el farmaco quimioterapeutico. | |
| JP2016531563A5 (zh) | ||
| JP2012532879A5 (zh) | ||
| WO2009053718A3 (en) | Immuno-modulatory composition | |
| CN101869558A (zh) | 二乙酰二脱水卫矛醇的抗血管生成及肿瘤转移作用 | |
| WO2019241641A3 (en) | Cancer treatment methods | |
| WO2015167215A3 (ko) | 복합 생약 추출물을 포함하는 조혈제 조성물 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20101027 |